Compounds > (10R,13S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
Page last updated: 2024-12-11
(10R,13S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
(10R,13S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one is a **synthetic steroid** with a very long and complex name. Let's break it down to understand its significance:
* **Structure:** The name reveals its chemical structure. It is built upon the **steroid skeleton**, a four-ring system (cyclopenta[a]phenanthrene) with specific modifications:
* **10R, 13S, 17R:** These letters and numbers indicate the stereochemistry of the molecule - the specific 3D arrangement of atoms.
* **17-ethynyl-17-hydroxy:** At position 17, there's an ethynyl group (C≡CH) and a hydroxyl group (OH).
* **13-methyl:** A methyl group (CH3) is attached at position 13.
* **1,2,6,7,8,9,10,11,12,14,15,16-dodecahydro:** This part indicates the presence of twelve hydrogen atoms attached to specific positions, creating a saturated ring system.
* **-3-one:** A ketone group (C=O) is present at position 3.
**Importance in Research:**
This steroid is of interest to researchers because of its potential applications in:
* **Drug Discovery:** It acts as a **potent agonist** for the **progesterone receptor** (PR). This means it binds to and activates the PR, mimicking the effects of progesterone. Progesterone plays crucial roles in female reproduction, menstruation, pregnancy, and other physiological processes.
* **Contraceptive Development:** Progesterone-based contraceptives are widely used, and new agonists with enhanced efficacy and fewer side effects are constantly being investigated. This specific steroid might be a promising candidate for such development.
* **Hormone Replacement Therapy (HRT):** It could be useful in treating conditions like menopause, where progesterone levels decline, and other hormonal imbalances.
* **Cancer Research:** Progesterone is involved in regulating cell growth and development. Understanding the mechanisms of its action could help in developing new cancer therapies targeting the PR.
**However, important points to remember:**
* This steroid is **not a marketed drug** currently. It is under research and further studies are required to assess its safety, effectiveness, and optimal dosage for various applications.
* Like all steroids, it could have potential side effects, and its long-term impact needs to be thoroughly studied.
In summary, (10R,13S,17R)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one is a complex synthetic steroid with promising potential in several medical fields, but more research is needed before its widespread application.
Cross-References
Synonyms (44)
Synonym |
BRD-A39415247-001-02-1 |
DIVK1C_000553 |
KBIO1_000553 |
SPECTRUM_001011 |
NCGC00178820-01 |
BSPBIO_002101 |
IDI1_000553 |
SPECTRUM5_001198 |
KBIO2_004059 |
KBIO2_001491 |
KBIO3_001601 |
KBIO2_006627 |
KBIOSS_001491 |
KBIOGR_000637 |
SPECTRUM3_000521 |
SPECTRUM2_001066 |
SPBIO_001052 |
NINDS_000553 |
SPECTRUM4_000079 |
SPECTRUM1500437 |
MLS001304093 |
smr000718762 |
HMS2091J10 |
17-ethynyl-17-hydroxyestr-4-en-3-one |
HMS501L15 |
(10r,13s,17r)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one |
HMS1920B10 |
AKOS004119895 |
CHEMBL2136460 |
nsc-757247 |
pharmakon1600-01500437 |
nsc757247 |
HMS2233N16 |
CCG-40102 |
AB00052056-05 |
AB00052056_07 |
sr-01000837542 |
SR-01000837542-2 |
CHEBI:91679 |
SBI-0051461.P003 |
Q27163501 |
BRD-A39415247-001-06-2 |
ES-2394 |
3-acetylamino-adamantane-1-carboxylicacid |
Roles (1)
Role | Description |
estrogen | A hormone that stimulates or controls the development and maintenance of female sex characteristics in mammals by binding to oestrogen receptors. The oestrogens are named for their importance in the oestrous cycle. The oestrogens that occur naturally in the body, notably estrone, estradiol, estriol, and estetrol are steroids. Other compounds with oestrogenic activity are produced by plants (phytoestrogens) and fungi (mycoestrogens); synthetic compounds with oestrogenic activity are known as xenoestrogens. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
steroid | Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene which is a triterpene. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (3)
Potency Measurements
Bioassays (16)
Assay ID | Title | Year | Journal | Article |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3
| High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
| A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.15
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.15 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.34 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |